Cargando…

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer

The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded several significant benefits for lung cancer patients, the emergence of resistance to EGFR-TKIs has been a substantial impedi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moonmuang, Sutpirat, Tantraworasin, Apichat, Orrapin, Santhasiri, Udomruk, Sasimol, Chewaskulyong, Busyamas, Pruksakorn, Dumnoensun, Chaiyawat, Parunya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003401/ https://www.ncbi.nlm.nih.gov/pubmed/36902280 http://dx.doi.org/10.3390/ijms24054827

Ejemplares similares

Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review
por: Orrapin, Santhasiri, et al.
Publicado: (2022)

Deciphering the Biology of Circulating Tumor Cells through Single-Cell RNA Sequencing: Implications for Precision Medicine in Cancer
por: Orrapin, Santhasiri, et al.
Publicado: (2023)

Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma
por: Moonmuang, Sutpirat, et al.
Publicado: (2021)

Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction
por: Sirikaew, Nutnicha, et al.
Publicado: (2022)

Prognostic score for life expectancy evaluation of lung cancer patients after bone metastasis
por: Pruksakorn, Dumnoensun, et al.
Publicado: (2017)

Descriptive epidemiology of soft tissue sarcomas and gastrointestinal stromal tumors in Thailand
por: Klangjorhor, Jeerawan, et al.
Publicado: (2022)

Exploring targeted therapy of osteosarcoma using proteomics data
por: Chaiyawat, Parunya, et al.
Publicado: (2017)

Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
por: Chaiyawat, Parunya, et al.
Publicado: (2018)

Surgical outcomes of extracorporeal irradiation and re-implantation in extremities for high grade osteosarcoma: A retrospective cohort study and a systematic review of the literature
por: Pruksakorn, Dumnoensun, et al.
Publicado: (2018)

Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2019)

Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2017)

Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2020)

Safety and efficacy of intralesional steroid injection for aggressive fibromatosis
por: Pruksakorn, Dumnoensun, et al.
Publicado: (2017)

IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2021)

Genomics-Driven Precision Medicine in Pediatric Solid Tumors
por: Suthapot, Praewa, et al.
Publicado: (2023)

Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma
por: Pruksakorn, Dumnoensun, et al.
Publicado: (2016)

Osteosarcoma-Specific Genes as a Diagnostic Tool and Clinical Predictor of Tumor Progression
por: Sittiju, Pattaralawan, et al.
Publicado: (2022)

Protein profiling of osteosarcoma tissue and soft callus unveils activation of the unfolded protein response pathway
por: Chaiyawat, Parunya, et al.
Publicado: (2019)

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
por: Cheong, Hio Teng, et al.
Publicado: (2018)

Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
por: Koonrungsesomboon, Nut, et al.
Publicado: (2020)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Sesamin Promotes Neurite Outgrowth under Insufficient Nerve Growth Factor Condition in PC12 Cells through ERK1/2 Pathway and SIRT1 Modulation
por: Udomruk, Sasimol, et al.
Publicado: (2020)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Giant cell tumour of the middle phalanx of the middle finger
por: Adulkasem, Nath, et al.
Publicado: (2019)

Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients
por: Cressey, Ratchada, et al.
Publicado: (2008)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
por: Yu, Tao, et al.
Publicado: (2020)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
por: Falk, Markus, et al.
Publicado: (2023)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study
por: Autsavapromporn, Narongchai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cblrftl0p7gr2b2rj75nc9jen6